Bayer, a multinational pharmaceutical company, and RTW Investments, a life science-focused investment firm, led a $162m Series D round in JIXING Pharmaceuticals, a biopharmaceutical company. “We are pleased to enter into this strategic partnership with Bayer, a leading multinational pharmaceutical company with a strong presence in China. Today’s milestones will help, strengthen JIXING's capabilities to develop and produce new drugs from preclinical stage to market launch, and enable us to rapidly expand our reach globally. We look forward to continuing to advance and deliver innovative therapies and solutions to patients,” Sandy Mou, JIXING Board Executive Director and CEO.